Semax Dosage in the Research Literature — Intranasal Routes and Half-Life
Dosage in the Semax Research Literature
Semax dosage in published rodent studies clusters in a narrow range. Intranasal Semax in rat BDNF studies was administered at 50 and 250 microg/kg [3]. Intraperitoneal Semax in ischemia studies was administered at 150 microg/kg [5]. Intraperitoneal dose ranges in dopamine and serotonin studies spanned 150-600 microg/kg [6]. None of these are human dosing recommendations — they are research administration protocols in laboratory rodents.
Russian clinical protocols for ischemic stroke use a different unit. The published pharmacopeia describes a regimen of approximately 6000 microg/day intranasal for 10 days, repeatable with a 20-day interval [21]. Russian clinical formulations are 0.1% or 1% intranasal solutions, with per-spray dose calculated against the indication. The full clinical record is documented in the Gusev 1997 trial protocol [7] and the Kaplan 2005 cerebrovascular insufficiency study [22].
Semax Nasal Spray: The Intranasal Route in Research
Semax nasal spray is the dominant route in both Russian clinical practice and the rodent research literature. Intranasal delivery offers a partial bypass of the blood-brain barrier via olfactory and trigeminal nerve pathways, which matters for a peptide whose plasma half-life is on the order of minutes. Shevchenko and colleagues showed that intranasal radiolabeled Semax delivered approximately 0.093% of the administered radioactivity per gram of rat brain tissue at 2 minutes post-dose, with about 80% remaining as intact Semax and the remainder as metabolites — chiefly the Pro-Gly-Pro tail [20].
Semax half-life
The Semax half-life in plasma is short — minutes in rat models — and the Pro-Gly-Pro tripeptide metabolite predominates in biological samples shortly after dosing [20]. That is the pharmacokinetic picture. The pharmacodynamic picture is different. Downstream effects on neurotrophin gene expression and EEG signatures persist for hours to days after a single intranasal dose [3][4][23]. The PD outlasts the PK by orders of magnitude. The reason is that Semax does not need to keep occupying receptors to maintain its effect — once the BDNF and NGF transcription has been initiated, the protein output and the synaptic changes persist far longer than the parent peptide does.
Onset of Semax effects
Intranasal pharmacokinetic studies in rats show CNS distribution within minutes [20]. Published human cognitive endpoints in the Russian clinical literature are typically measured 20-60 minutes post-administration. EEG changes have been documented in healthy volunteers after intranasal dosing, with reproducible spectrum shifts consistent with central nootropic action [23].
Duration of action per published Semax pharmacokinetics
Plasma clearance is rapid — under an hour in rat models for the parent peptide [20]. Central effects on gene expression and neurotrophic factors persist for hours to days after a single intranasal dose [3][10]. The Romanova six-day intranasal course in the rat focal-ischemia model produced sustained neuroprotection and memory preservation [11], indicating that repeated dosing builds on the prior day's transcriptional signal rather than requiring continuous plasma exposure.
Treatment duration in published Semax trials
Published Russian protocols range from single-dose acute-stroke administration through 10-day intranasal courses to multi-week regimens for chronic cerebrovascular insufficiency [7][22]. Long-term safety data beyond the 10-day acute-care window are limited in the indexed literature. The Kaplan 2005 six-month prospective study reported reduced exacerbation frequency in cerebrovascular insufficiency patients, with no major safety signals reported in the paper's summary [22] — though it was open-label and modestly powered.
Intranasal Semax preparation in research settings
Research protocols describe reconstitution of lyophilized Semax in bacteriostatic water or saline, with concentration chosen to deliver the target microgram dose per spray actuation. Russian clinical formulations are 0.1% (1 mg/mL) and 1% (10 mg/mL) intranasal solutions, delivered via metered-dose intranasal sprays. The actual mechanical preparation procedure is a laboratory technique, not a personal-use recipe — laboratories use sterile water for injection, calibrated pipettes, and pH-buffered diluents per Russian pharmacopeia descriptions [21].
Reconstitution practices in Semax research
Lyophilized Semax is reconstituted with bacteriostatic water in laboratory protocols, with concentration calculated to match the study's intended per-spray dose. The Pro-Gly-Pro tail confers proteolytic stability versus the bare ACTH 4-10 fragment, but reconstituted solutions remain peptides — typically stored refrigerated to preserve integrity, used within the windows specified in the study protocol.
Dosing in published Semax research
The vast majority of published clinical work uses the intranasal route; injectable Semax dosing is not a primary feature of the literature. Reported intranasal doses in human trials span roughly 250-1500 microg per session, with daily totals reaching ~6000 microg in the stroke-recovery protocol [21]. The rodent intraperitoneal dose range (150-600 microg/kg) does not translate directly to a human intranasal dose — the route, the species, and the bioavailability differ.